EP1667729A2 - Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 - Google Patents
Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1Info
- Publication number
- EP1667729A2 EP1667729A2 EP04776088A EP04776088A EP1667729A2 EP 1667729 A2 EP1667729 A2 EP 1667729A2 EP 04776088 A EP04776088 A EP 04776088A EP 04776088 A EP04776088 A EP 04776088A EP 1667729 A2 EP1667729 A2 EP 1667729A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- antigen
- thioaptamer
- virus
- immune response
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 108091023040 Transcription factor Proteins 0.000 title claims abstract description 40
- 102000040945 Transcription factor Human genes 0.000 title claims abstract description 39
- 108091023037 Aptamer Proteins 0.000 title claims description 144
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 title description 34
- 230000008685 targeting Effects 0.000 title description 14
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 title description 5
- 238000000034 method Methods 0.000 claims abstract description 106
- 239000000203 mixture Substances 0.000 claims abstract description 77
- 102000003945 NF-kappa B Human genes 0.000 claims abstract description 57
- 108010057466 NF-kappa B Proteins 0.000 claims abstract description 57
- 229960005486 vaccine Drugs 0.000 claims abstract description 41
- 108090001005 Interleukin-6 Proteins 0.000 claims abstract description 24
- 230000009385 viral infection Effects 0.000 claims abstract description 22
- 208000036142 Viral infection Diseases 0.000 claims abstract description 14
- 230000004044 response Effects 0.000 claims abstract description 14
- 108010018242 Transcription Factor AP-1 Proteins 0.000 claims abstract 3
- 108090000623 proteins and genes Proteins 0.000 claims description 181
- 102000004169 proteins and genes Human genes 0.000 claims description 175
- 241000700605 Viruses Species 0.000 claims description 104
- 210000004027 cell Anatomy 0.000 claims description 79
- 230000027455 binding Effects 0.000 claims description 78
- 239000000427 antigen Substances 0.000 claims description 75
- 108091007433 antigens Proteins 0.000 claims description 69
- 102000036639 antigens Human genes 0.000 claims description 69
- 230000028993 immune response Effects 0.000 claims description 64
- 125000003729 nucleotide group Chemical group 0.000 claims description 37
- 239000002671 adjuvant Substances 0.000 claims description 36
- 108020004414 DNA Proteins 0.000 claims description 35
- 230000000694 effects Effects 0.000 claims description 31
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 27
- -1 RBP-Jκ Proteins 0.000 claims description 26
- 239000002773 nucleotide Substances 0.000 claims description 26
- 102000004889 Interleukin-6 Human genes 0.000 claims description 23
- 230000015788 innate immune response Effects 0.000 claims description 23
- 239000002502 liposome Substances 0.000 claims description 23
- 238000012986 modification Methods 0.000 claims description 21
- 230000004048 modification Effects 0.000 claims description 20
- 230000001717 pathogenic effect Effects 0.000 claims description 19
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 18
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 18
- 102000052510 DNA-Binding Proteins Human genes 0.000 claims description 16
- 210000002540 macrophage Anatomy 0.000 claims description 16
- 230000004913 activation Effects 0.000 claims description 15
- 230000001225 therapeutic effect Effects 0.000 claims description 15
- 206010028980 Neoplasm Diseases 0.000 claims description 14
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 14
- 230000002981 neuropathic effect Effects 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 101710096438 DNA-binding protein Proteins 0.000 claims description 13
- 230000005867 T cell response Effects 0.000 claims description 13
- 201000011510 cancer Diseases 0.000 claims description 13
- 238000001727 in vivo Methods 0.000 claims description 13
- 150000007523 nucleic acids Chemical group 0.000 claims description 13
- 241000710886 West Nile virus Species 0.000 claims description 12
- 244000052769 pathogen Species 0.000 claims description 11
- 102000002689 Toll-like receptor Human genes 0.000 claims description 10
- 108020000411 Toll-like receptor Proteins 0.000 claims description 10
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 10
- 239000002158 endotoxin Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 102100023132 Transcription factor Jun Human genes 0.000 claims description 9
- 239000003981 vehicle Substances 0.000 claims description 9
- 102000013462 Interleukin-12 Human genes 0.000 claims description 8
- 108010065805 Interleukin-12 Proteins 0.000 claims description 8
- 230000002238 attenuated effect Effects 0.000 claims description 8
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 241000233866 Fungi Species 0.000 claims description 7
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 7
- 229940117681 interleukin-12 Drugs 0.000 claims description 7
- 102000037983 regulatory factors Human genes 0.000 claims description 7
- 108091008025 regulatory factors Proteins 0.000 claims description 7
- 241001430294 unidentified retrovirus Species 0.000 claims description 7
- 201000009695 Argentine hemorrhagic fever Diseases 0.000 claims description 6
- 101000584743 Homo sapiens Recombining binding protein suppressor of hairless Proteins 0.000 claims description 6
- 102100030000 Recombining binding protein suppressor of hairless Human genes 0.000 claims description 6
- 230000003834 intracellular effect Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 5
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 5
- 230000033289 adaptive immune response Effects 0.000 claims description 5
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 5
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 5
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 4
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 4
- 102000000588 Interleukin-2 Human genes 0.000 claims description 4
- 108010002350 Interleukin-2 Proteins 0.000 claims description 4
- 102000000646 Interleukin-3 Human genes 0.000 claims description 4
- 108010002386 Interleukin-3 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 108010002616 Interleukin-5 Proteins 0.000 claims description 4
- 230000006044 T cell activation Effects 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 210000004443 dendritic cell Anatomy 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 238000007911 parenteral administration Methods 0.000 claims description 4
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000003829 American Hemorrhagic Fever Diseases 0.000 claims description 3
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 208000034200 Bolivian hemorrhagic fever Diseases 0.000 claims description 3
- 241000283073 Equus caballus Species 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 3
- 108010074328 Interferon-gamma Proteins 0.000 claims description 3
- 102000003814 Interleukin-10 Human genes 0.000 claims description 3
- 108090000174 Interleukin-10 Proteins 0.000 claims description 3
- 102000003815 Interleukin-11 Human genes 0.000 claims description 3
- 108090000177 Interleukin-11 Proteins 0.000 claims description 3
- 102000003816 Interleukin-13 Human genes 0.000 claims description 3
- 108090000176 Interleukin-13 Proteins 0.000 claims description 3
- 108010002586 Interleukin-7 Proteins 0.000 claims description 3
- 102000004890 Interleukin-8 Human genes 0.000 claims description 3
- 108090001007 Interleukin-8 Proteins 0.000 claims description 3
- 241000712902 Lassa mammarenavirus Species 0.000 claims description 3
- 208000011448 Omsk hemorrhagic fever Diseases 0.000 claims description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 3
- 244000308495 Potentilla anserina Species 0.000 claims description 3
- 235000016594 Potentilla anserina Nutrition 0.000 claims description 3
- 208000000705 Rift Valley Fever Diseases 0.000 claims description 3
- 201000009693 Venezuelan hemorrhagic fever Diseases 0.000 claims description 3
- 230000036783 anaphylactic response Effects 0.000 claims description 3
- 208000003455 anaphylaxis Diseases 0.000 claims description 3
- 239000008135 aqueous vehicle Substances 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 230000005931 immune cell recruitment Effects 0.000 claims description 3
- 230000016784 immunoglobulin production Effects 0.000 claims description 3
- 238000007918 intramuscular administration Methods 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 230000001404 mediated effect Effects 0.000 claims description 3
- 108020004999 messenger RNA Proteins 0.000 claims description 3
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 238000007920 subcutaneous administration Methods 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 208000026872 Addison Disease Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 102100022987 Angiogenin Human genes 0.000 claims description 2
- 102400000068 Angiostatin Human genes 0.000 claims description 2
- 108010079709 Angiostatins Proteins 0.000 claims description 2
- 206010003594 Ataxia telangiectasia Diseases 0.000 claims description 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 claims description 2
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims description 2
- 102100035526 B melanoma antigen 1 Human genes 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000023328 Basedow disease Diseases 0.000 claims description 2
- 201000010424 Brazilian hemorrhagic fever Diseases 0.000 claims description 2
- 208000008889 California Encephalitis Diseases 0.000 claims description 2
- 241001493160 California encephalitis virus Species 0.000 claims description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims description 2
- 206010008609 Cholangitis sclerosing Diseases 0.000 claims description 2
- 208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 claims description 2
- 206010010685 Congo-Crimean haemorrhagic fever Diseases 0.000 claims description 2
- 208000000307 Crimean Hemorrhagic Fever Diseases 0.000 claims description 2
- 201000003075 Crimean-Congo hemorrhagic fever Diseases 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims description 2
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 claims description 2
- 201000005804 Eastern equine encephalitis Diseases 0.000 claims description 2
- 206010014584 Encephalitis california Diseases 0.000 claims description 2
- 206010014587 Encephalitis eastern equine Diseases 0.000 claims description 2
- 206010014614 Encephalitis western equine Diseases 0.000 claims description 2
- 102400001047 Endostatin Human genes 0.000 claims description 2
- 108010079505 Endostatins Proteins 0.000 claims description 2
- 208000000832 Equine Encephalomyelitis Diseases 0.000 claims description 2
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 claims description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 2
- 208000015023 Graves' disease Diseases 0.000 claims description 2
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 2
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 claims description 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims description 2
- 101000654734 Homo sapiens Septin-4 Proteins 0.000 claims description 2
- 102000002227 Interferon Type I Human genes 0.000 claims description 2
- 108010014726 Interferon Type I Proteins 0.000 claims description 2
- 241001494444 Jamestown Canyon virus Species 0.000 claims description 2
- 241001494421 Keystone virus Species 0.000 claims description 2
- 201000009908 La Crosse encephalitis Diseases 0.000 claims description 2
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 102000004083 Lymphotoxin-alpha Human genes 0.000 claims description 2
- 108090000542 Lymphotoxin-alpha Proteins 0.000 claims description 2
- 241000712898 Machupo mammarenavirus Species 0.000 claims description 2
- 108050008953 Melanoma-associated antigen Proteins 0.000 claims description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 2
- 206010028080 Mucocutaneous candidiasis Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 241000721454 Pemphigus Species 0.000 claims description 2
- 208000031845 Pernicious anaemia Diseases 0.000 claims description 2
- 102100026918 Phospholipase A2 Human genes 0.000 claims description 2
- 108010058864 Phospholipases A2 Proteins 0.000 claims description 2
- 201000009754 Powassan encephalitis Diseases 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 241000192617 Sabia mammarenavirus Species 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 241000713134 Snowshoe hare virus Species 0.000 claims description 2
- 206010041896 St. Louis Encephalitis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims description 2
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims description 2
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 2
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 2
- 108010060888 Toll-like receptor 2 Proteins 0.000 claims description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 claims description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 claims description 2
- 102400001320 Transforming growth factor alpha Human genes 0.000 claims description 2
- 101800004564 Transforming growth factor alpha Proteins 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 241001494427 Trivittatus virus Species 0.000 claims description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 2
- 102100039094 Tyrosinase Human genes 0.000 claims description 2
- 108060008724 Tyrosinase Proteins 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 206010046851 Uveitis Diseases 0.000 claims description 2
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 claims description 2
- 201000005806 Western equine encephalitis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 206010002022 amyloidosis Diseases 0.000 claims description 2
- 108010072788 angiogenin Proteins 0.000 claims description 2
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 2
- 235000014633 carbohydrates Nutrition 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 231100000655 enterotoxin Toxicity 0.000 claims description 2
- 230000008472 epithelial growth Effects 0.000 claims description 2
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 210000003714 granulocyte Anatomy 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims description 2
- 231100000283 hepatitis Toxicity 0.000 claims description 2
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 238000012737 microarray-based gene expression Methods 0.000 claims description 2
- 239000003094 microcapsule Substances 0.000 claims description 2
- 230000005012 migration Effects 0.000 claims description 2
- 238000013508 migration Methods 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 238000012243 multiplex automated genomic engineering Methods 0.000 claims description 2
- 201000008383 nephritis Diseases 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 210000003786 sclera Anatomy 0.000 claims description 2
- 208000010157 sclerosing cholangitis Diseases 0.000 claims description 2
- MJNIWUJSIGSWKK-UHFFFAOYSA-N Riboflavine 2',3',4',5'-tetrabutanoate Chemical compound CCCC(=O)OCC(OC(=O)CCC)C(OC(=O)CCC)C(OC(=O)CCC)CN1C2=CC(C)=C(C)C=C2N=C2C1=NC(=O)NC2=O MJNIWUJSIGSWKK-UHFFFAOYSA-N 0.000 claims 14
- 229940100601 interleukin-6 Drugs 0.000 claims 9
- 102000000589 Interleukin-1 Human genes 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 102100039897 Interleukin-5 Human genes 0.000 claims 2
- 102100021592 Interleukin-7 Human genes 0.000 claims 2
- 102100020847 Protein FosB Human genes 0.000 claims 2
- 229940076144 interleukin-10 Drugs 0.000 claims 2
- 229940074383 interleukin-11 Drugs 0.000 claims 2
- 229940076264 interleukin-3 Drugs 0.000 claims 2
- 229940028885 interleukin-4 Drugs 0.000 claims 2
- 229940100602 interleukin-5 Drugs 0.000 claims 2
- 229940100994 interleukin-7 Drugs 0.000 claims 2
- 229940096397 interleukin-8 Drugs 0.000 claims 2
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 claims 2
- 201000007155 CD40 ligand deficiency Diseases 0.000 claims 1
- 101100150281 Caenorhabditis elegans sre-38 gene Proteins 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 241001115402 Ebolavirus Species 0.000 claims 1
- 101000852852 Homo sapiens Innate immunity activator protein Proteins 0.000 claims 1
- 102100036724 Innate immunity activator protein Human genes 0.000 claims 1
- 208000003140 Kyasanur forest disease Diseases 0.000 claims 1
- 241001115401 Marburgvirus Species 0.000 claims 1
- 208000006391 Type 1 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 1
- 208000006110 Wiskott-Aldrich syndrome Diseases 0.000 claims 1
- 201000001696 X-linked hyper IgM syndrome Diseases 0.000 claims 1
- 241000710772 Yellow fever virus Species 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 208000026095 hyper-IgM syndrome type 1 Diseases 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 208000016367 transient hypogammaglobulinemia of infancy Diseases 0.000 claims 1
- 229940051021 yellow-fever virus Drugs 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 21
- 238000011282 treatment Methods 0.000 abstract description 14
- 230000005745 host immune response Effects 0.000 abstract description 4
- 239000012646 vaccine adjuvant Substances 0.000 abstract description 2
- 229940124931 vaccine adjuvant Drugs 0.000 abstract description 2
- 239000011324 bead Substances 0.000 description 208
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 60
- 101710123496 Spindolin Proteins 0.000 description 60
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 55
- 239000003795 chemical substances by application Substances 0.000 description 53
- 239000000284 extract Substances 0.000 description 50
- 238000003752 polymerase chain reaction Methods 0.000 description 30
- 208000015181 infectious disease Diseases 0.000 description 27
- 229910019142 PO4 Inorganic materials 0.000 description 26
- 108091034117 Oligonucleotide Proteins 0.000 description 25
- 239000000499 gel Substances 0.000 description 24
- 235000021317 phosphate Nutrition 0.000 description 24
- 239000003814 drug Substances 0.000 description 23
- 102000004127 Cytokines Human genes 0.000 description 22
- 108090000695 Cytokines Proteins 0.000 description 22
- 101710124574 Synaptotagmin-1 Proteins 0.000 description 22
- 102100035100 Transcription factor p65 Human genes 0.000 description 22
- 238000000684 flow cytometry Methods 0.000 description 22
- 239000010452 phosphate Substances 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 20
- 239000000975 dye Substances 0.000 description 20
- 239000000539 dimer Substances 0.000 description 19
- 201000010099 disease Diseases 0.000 description 19
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 238000004949 mass spectrometry Methods 0.000 description 19
- 230000003612 virological effect Effects 0.000 description 19
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical compound OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 18
- 238000000338 in vitro Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 239000004480 active ingredient Substances 0.000 description 16
- 230000001413 cellular effect Effects 0.000 description 16
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 16
- 239000002953 phosphate buffered saline Substances 0.000 description 16
- 238000006467 substitution reaction Methods 0.000 description 16
- 238000003786 synthesis reaction Methods 0.000 description 16
- 101710163270 Nuclease Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 15
- 235000002639 sodium chloride Nutrition 0.000 description 15
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 description 14
- 230000004083 survival effect Effects 0.000 description 14
- 238000013459 approach Methods 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 241000700198 Cavia Species 0.000 description 12
- 108010026552 Proteome Proteins 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 239000000710 homodimer Substances 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 12
- 239000000523 sample Substances 0.000 description 12
- 238000001920 surface-enhanced laser desorption--ionisation mass spectrometry Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 241000712891 Arenavirus Species 0.000 description 11
- 101500027983 Rattus norvegicus Octadecaneuropeptide Proteins 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 235000001508 sulfur Nutrition 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 9
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 9
- 101710191478 Cytidylate kinase 1 Proteins 0.000 description 9
- 102100033295 Glial cell line-derived neurotrophic factor Human genes 0.000 description 9
- 102100022905 Keratin, type II cytoskeletal 1 Human genes 0.000 description 9
- 101710194922 Keratin, type II cytoskeletal 1 Proteins 0.000 description 9
- 206010023927 Lassa fever Diseases 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 9
- 101710201870 UMP-CMP kinase 1 Proteins 0.000 description 9
- 230000000840 anti-viral effect Effects 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 238000001514 detection method Methods 0.000 description 9
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 9
- 150000008300 phosphoramidites Chemical class 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 206010058874 Viraemia Diseases 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- 239000002775 capsule Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 230000003993 interaction Effects 0.000 description 8
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 239000011593 sulfur Substances 0.000 description 8
- 229910052717 sulfur Inorganic materials 0.000 description 8
- 239000012103 Alexa Fluor 488 Substances 0.000 description 7
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 7
- 230000004568 DNA-binding Effects 0.000 description 7
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 7
- 238000003491 array Methods 0.000 description 7
- 229940095074 cyclic amp Drugs 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 230000006698 induction Effects 0.000 description 7
- 229920006008 lipopolysaccharide Polymers 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 230000009871 nonspecific binding Effects 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 230000008506 pathogenesis Effects 0.000 description 7
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 102000005395 NF-kappa B p50 Subunit Human genes 0.000 description 6
- 108010006401 NF-kappa B p50 Subunit Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 241000712910 Pichinde mammarenavirus Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 6
- 238000012512 characterization method Methods 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 230000037361 pathway Effects 0.000 description 6
- 150000004713 phosphodiesters Chemical class 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010187 selection method Methods 0.000 description 6
- 238000012163 sequencing technique Methods 0.000 description 6
- 230000011664 signaling Effects 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 238000005987 sulfurization reaction Methods 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 238000004885 tandem mass spectrometry Methods 0.000 description 6
- 238000002255 vaccination Methods 0.000 description 6
- 230000029812 viral genome replication Effects 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 241000710831 Flavivirus Species 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010061192 Haemorrhagic fever Diseases 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 230000008878 coupling Effects 0.000 description 5
- 238000010168 coupling process Methods 0.000 description 5
- 238000005859 coupling reaction Methods 0.000 description 5
- 230000007423 decrease Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 239000003085 diluting agent Substances 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 229940079322 interferon Drugs 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 230000017854 proteolysis Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 239000000829 suppository Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 4
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 4
- 102100038968 WAP four-disulfide core domain protein 1 Human genes 0.000 description 4
- 206010057293 West Nile viral infection Diseases 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 230000000120 cytopathologic effect Effects 0.000 description 4
- 230000001086 cytosolic effect Effects 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000007850 fluorescent dye Substances 0.000 description 4
- 210000001035 gastrointestinal tract Anatomy 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000008297 liquid dosage form Substances 0.000 description 4
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 239000002777 nucleoside Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- 230000000770 proinflammatory effect Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108020000946 Bacterial DNA Proteins 0.000 description 3
- 102000015280 CCAAT-Enhancer-Binding Protein-beta Human genes 0.000 description 3
- 108010064535 CCAAT-Enhancer-Binding Protein-beta Proteins 0.000 description 3
- 102100023580 Cyclic AMP-dependent transcription factor ATF-4 Human genes 0.000 description 3
- 108700020911 DNA-Binding Proteins Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000004593 Epoxy Substances 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 108091010837 Glial cell line-derived neurotrophic factor Proteins 0.000 description 3
- 101000905743 Homo sapiens Cyclic AMP-dependent transcription factor ATF-4 Proteins 0.000 description 3
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 3
- 241001244466 New world arenaviruses Species 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- 102000001253 Protein Kinase Human genes 0.000 description 3
- 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 3
- 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 206010040070 Septic Shock Diseases 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 3
- 239000012190 activator Substances 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 238000013528 artificial neural network Methods 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 238000003795 desorption Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 101150064107 fosB gene Proteins 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 231100000636 lethal dose Toxicity 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 150000003833 nucleoside derivatives Chemical class 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 108060006633 protein kinase Proteins 0.000 description 3
- 239000010979 ruby Substances 0.000 description 3
- 229910001750 ruby Inorganic materials 0.000 description 3
- 239000004065 semiconductor Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000015936 AP-1 transcription factor Human genes 0.000 description 2
- 108050004195 AP-1 transcription factor Proteins 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 108010080691 Alcohol O-acetyltransferase Proteins 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000005989 Arenaviridae Infections Diseases 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000000806 Basic-Leucine Zipper Transcription Factors Human genes 0.000 description 2
- 108010001572 Basic-Leucine Zipper Transcription Factors Proteins 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108091035707 Consensus sequence Proteins 0.000 description 2
- 244000304337 Cuminum cyminum Species 0.000 description 2
- 102100023583 Cyclic AMP-dependent transcription factor ATF-6 alpha Human genes 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 2
- 206010014824 Endotoxic shock Diseases 0.000 description 2
- 101150096607 Fosl2 gene Proteins 0.000 description 2
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 2
- 101150043052 Hamp gene Proteins 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000905751 Homo sapiens Cyclic AMP-dependent transcription factor ATF-6 alpha Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 2
- 101150021395 JUND gene Proteins 0.000 description 2
- 241000712890 Junin mammarenavirus Species 0.000 description 2
- 241001466978 Kyasanur forest disease virus Species 0.000 description 2
- 102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
- 108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 2
- 241000725177 Omsk hemorrhagic fever virus Species 0.000 description 2
- 229920000954 Polyglycolide Polymers 0.000 description 2
- 108010016131 Proto-Oncogene Proteins c-jun Proteins 0.000 description 2
- 102000000427 Proto-Oncogene Proteins c-jun Human genes 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 108091027981 Response element Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 2
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 2
- 230000010632 Transcription Factor Activity Effects 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 2
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 241000120645 Yellow fever virus group Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 208000024597 arenavirus hemorrhagic fever Diseases 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000033077 cellular process Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 150000001793 charged compounds Chemical class 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 2
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 150000005690 diesters Chemical group 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 239000012154 double-distilled water Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000007938 effervescent tablet Substances 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 238000000799 fluorescence microscopy Methods 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007897 gelcap Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 239000000833 heterodimer Substances 0.000 description 2
- IKGLACJFEHSFNN-UHFFFAOYSA-N hydron;triethylazanium;trifluoride Chemical compound F.F.F.CCN(CC)CC IKGLACJFEHSFNN-UHFFFAOYSA-N 0.000 description 2
- 230000005934 immune activation Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 230000003308 immunostimulating effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000012804 iterative process Methods 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000004811 liquid chromatography Methods 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 238000002493 microarray Methods 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 238000002414 normal-phase solid-phase extraction Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000003182 parenteral nutrition solution Substances 0.000 description 2
- 150000003014 phosphoric acid esters Chemical class 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 2
- 230000026731 phosphorylation Effects 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000747 poly(lactic acid) Polymers 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004633 polyglycolic acid Substances 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000002331 protein detection Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000009490 roller compaction Methods 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000036964 tight binding Effects 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- QZCJOXAIQXPLNS-UHFFFAOYSA-N 1,1,2,2,3,3,4,4,4a,5,5,6,6,7,7,8,8,8a-octadecafluoronaphthalene 4-(2-aminoethyl)benzene-1,2-diol Chemical compound NCCc1ccc(O)c(O)c1.FC1(F)C(F)(F)C(F)(F)C2(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C2(F)C1(F)F QZCJOXAIQXPLNS-UHFFFAOYSA-N 0.000 description 1
- JUDOLRSMWHVKGX-UHFFFAOYSA-N 1,1-dioxo-1$l^{6},2-benzodithiol-3-one Chemical compound C1=CC=C2C(=O)SS(=O)(=O)C2=C1 JUDOLRSMWHVKGX-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Chemical compound C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
- XGDRLCRGKUCBQL-UHFFFAOYSA-N 1h-imidazole-4,5-dicarbonitrile Chemical compound N#CC=1N=CNC=1C#N XGDRLCRGKUCBQL-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- QSECPQCFCWVBKM-UHFFFAOYSA-N 2-iodoethanol Chemical compound OCCI QSECPQCFCWVBKM-UHFFFAOYSA-N 0.000 description 1
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 102000039549 ATF family Human genes 0.000 description 1
- 108091067350 ATF family Proteins 0.000 description 1
- 102100027211 Albumin Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000033399 Anaphylactic responses Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 101100449517 Arabidopsis thaliana GRH1 gene Proteins 0.000 description 1
- 241000712892 Arenaviridae Species 0.000 description 1
- 208000006740 Aseptic Meningitis Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102100022970 Basic leucine zipper transcriptional factor ATF-like Human genes 0.000 description 1
- 108050003758 Basic leucine zipper transcriptional factor ATF-like Proteins 0.000 description 1
- 102100023013 Basic leucine zipper transcriptional factor ATF-like 3 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710186200 CCAAT/enhancer-binding protein Proteins 0.000 description 1
- 241001600492 Cache Valley virus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 201000005488 Capillary Leak Syndrome Diseases 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 241000037164 Collema parvum Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 108091029523 CpG island Proteins 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010017826 DNA Polymerase I Proteins 0.000 description 1
- 102000004594 DNA Polymerase I Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 101100129232 Danio rerio mafaa gene Proteins 0.000 description 1
- 241000408659 Darpa Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 241000255925 Diptera Species 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 208000037487 Endotoxemia Diseases 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 102000039539 Fos family Human genes 0.000 description 1
- 108091067362 Fos family Proteins 0.000 description 1
- 108090000123 Fos-related antigen 1 Proteins 0.000 description 1
- 102000003817 Fos-related antigen 1 Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000190708 Guanarito mammarenavirus Species 0.000 description 1
- 101000903609 Homo sapiens Basic leucine zipper transcriptional factor ATF-like 3 Proteins 0.000 description 1
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 1
- 101000870234 Homo sapiens DnaJ homolog subfamily C member 12 Proteins 0.000 description 1
- 101000975509 Homo sapiens Jun dimerization protein 2 Proteins 0.000 description 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
- 101000800479 Homo sapiens Toll-like receptor 9 Proteins 0.000 description 1
- 101001057744 Human cytomegalovirus (strain AD169) Uncharacterized protein IRL9 Proteins 0.000 description 1
- 208000003352 Hyper-IgM Immunodeficiency Syndrome Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 1
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 1
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 1
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 1
- 101150026829 JUNB gene Proteins 0.000 description 1
- 102100023976 Jun dimerization protein 2 Human genes 0.000 description 1
- 101150051019 Klrg1 gene Proteins 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 101150084866 MAFA gene Proteins 0.000 description 1
- 101150022636 MAFB gene Proteins 0.000 description 1
- 101150069805 MAFG gene Proteins 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- 102000007307 Maf Transcription Factors Human genes 0.000 description 1
- 108010033714 Maf Transcription Factors Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000003773 Meningism Diseases 0.000 description 1
- 206010027201 Meningitis aseptic Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000007474 Multiprotein Complexes Human genes 0.000 description 1
- 108010085220 Multiprotein Complexes Proteins 0.000 description 1
- 101001054328 Mus musculus Interferon beta Proteins 0.000 description 1
- 101100260758 Mus musculus Tlr9 gene Proteins 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 1
- 102000002673 NFATC Transcription Factors Human genes 0.000 description 1
- 108010018525 NFATC Transcription Factors Proteins 0.000 description 1
- 208000008457 Neurologic Manifestations Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 102000011779 Nitric Oxide Synthase Type II Human genes 0.000 description 1
- 108010076864 Nitric Oxide Synthase Type II Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000015731 Peptide Hormones Human genes 0.000 description 1
- 108010038988 Peptide Hormones Proteins 0.000 description 1
- 241000150350 Peribunyaviridae Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000007987 Proto-Oncogene Proteins c-maf Human genes 0.000 description 1
- 108010089507 Proto-Oncogene Proteins c-maf Proteins 0.000 description 1
- 102000000850 Proto-Oncogene Proteins c-rel Human genes 0.000 description 1
- 108010001859 Proto-Oncogene Proteins c-rel Proteins 0.000 description 1
- 101710086015 RNA ligase Proteins 0.000 description 1
- 101100380517 Rattus norvegicus Atf3 gene Proteins 0.000 description 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
- 241000713124 Rift Valley fever virus Species 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
- 208000031932 Systemic capillary leak syndrome Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229910052770 Uranium Inorganic materials 0.000 description 1
- 206010047141 Vasodilatation Diseases 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LUXUAZKGQZPOBZ-SAXJAHGMSA-N [(3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (Z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@@H]1O LUXUAZKGQZPOBZ-SAXJAHGMSA-N 0.000 description 1
- PXHHTOSRELKWOE-MXWQNOQOSA-N [hydroxy-[[(2r,3s,5r)-3-hydroxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy]phosphinothioyl] phosphono hydrogen phosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=S)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 PXHHTOSRELKWOE-MXWQNOQOSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010398 acute inflammatory response Effects 0.000 description 1
- 230000004658 acute-phase response Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 230000007416 antiviral immune response Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 235000012216 bentonite Nutrition 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000019846 buffering salt Nutrition 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 230000004715 cellular signal transduction Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical class NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000008260 defense mechanism Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 230000009699 differential effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 125000004119 disulfanediyl group Chemical group *SS* 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 238000012869 ethanol precipitation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000017188 evasion or tolerance of host immune response Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000003328 fibroblastic effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000012632 fluorescent imaging Methods 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000011554 guinea pig model Methods 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000047410 human NFKB1 Human genes 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 206010066130 hyper-IgM syndrome Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000006450 immune cell response Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000010468 interferon response Effects 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 230000017306 interleukin-6 production Effects 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000013227 macrophage apoptotic process Effects 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 208000023158 meningismus Diseases 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000008185 minitablet Substances 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 150000004712 monophosphates Chemical class 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 108700029353 mouse Ifna Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000000491 multivariate analysis Methods 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 239000013631 noncovalent dimer Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 210000003024 peritoneal macrophage Anatomy 0.000 description 1
- 230000003094 perturbing effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008105 phosphatidylcholines Chemical class 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920006324 polyoxymethylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000013636 protein dimer Substances 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 230000012121 regulation of immune response Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000003307 reticuloendothelial effect Effects 0.000 description 1
- 229960000329 ribavirin Drugs 0.000 description 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 230000009131 signaling function Effects 0.000 description 1
- PCMORTLOPMLEFB-ONEGZZNKSA-N sinapic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-ONEGZZNKSA-N 0.000 description 1
- PCMORTLOPMLEFB-UHFFFAOYSA-N sinapinic acid Natural products COC1=CC(C=CC(O)=O)=CC(OC)=C1O PCMORTLOPMLEFB-UHFFFAOYSA-N 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000012799 strong cation exchange Methods 0.000 description 1
- 238000012437 strong cation exchange chromatography Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- BIIUNHCUZONUSM-UHFFFAOYSA-N sulfanylphosphonamidous acid Chemical class NP(O)S BIIUNHCUZONUSM-UHFFFAOYSA-N 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 238000009120 supportive therapy Methods 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000037317 transdermal delivery Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 238000001419 two-dimensional polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 239000002691 unilamellar liposome Substances 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000003501 vero cell Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/13—Decoys
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/16—Aptamers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/10—Applications; Uses in screening processes
- C12N2320/11—Applications; Uses in screening processes for the determination of target sites, i.e. of active nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/30—Production chemically synthesised
- C12N2330/31—Libraries, arrays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/12011—Bunyaviridae
- C12N2760/12211—Phlebovirus, e.g. Rift Valley fever virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- Arenavirus Hemorrhagic Fevers such as Lassa fever, Junin, Argentine hemorrhagic fever, Venezuelan hemorrhagic fever, have several features in common with sepsis and the systemic inflammatory response syndrome, including fulminant clinical course, fever, shock, capillary leak syndrome, decreased myocardial contractility, abnormalities of coagulation and platelet function, and elevated serum levels of TNF ⁇ (Aronson et al., 1994; Cummins, 1990).
- Arenaviruses are non-cytopathic viruses with a tropism for macrophages and other reticuloendothelial cells (Cummins, 1990; Peters et al., 1987); the pathogenesis of these diseases is believed to involve excessive production of pro-inflammatory cytokines (Aronson et al., 1995; Peters et al., 1987). Unpublished data (Bausch et al., CDC) show cytokines to be massively activated in human Lassa fever, and also confirm that Lassa virus can directly induce cytokine secretion by infecting human macrophages in vitro (Mahanty et al., CDC, unpublished).
- Endotoxic shock results from an innate, anaphylactic response to bacterial lipopolysaccharide (LPS).
- LPS lipopolysaccharide
- NF- B activation figures A series of intracellular signaling events, in which NF- B activation figures importantly leads to enhanced transcription of proinfiammatory mediators, including TNF ⁇ , IL-1 and inducible nitric oxide synthase, ultimately promoting vasodilatation, capillary leakiness, and myocardial suppression
- DNA-binding activity can be detected in the nuclei of macrophages and other cell types (Boher, et al., 1997); similar observations have been made in human sepsis (Velasco et al., 1997).
- the AP-1 transcription factor family include the dimeric basic region leucine zipper proteins that belong to the Jun (c-Jun, JunB, JunD), Fos (c-Fos, FosB, Fra-1, Fra-2) Maf (c-Maf, MafB, MafA, MafG/F/K, Nrl) and ATF/CREB (CREB, CREBP-2, ATF1, ATF2, LRF1/ATF3, ATF4, ATFa, ATF6, B-ATF, JDP1, JDP2) subfamilies which recognize either 12-0-tetradecanoylphorbol-13-acetate (TPA) response elements (5'-TGAG/CTCA-3') or cAMP response elements (CRE, 5'-TGACGTCA-3') (Chinenov and Kerppola, 2001; Shaulian and Karin, 2002).
- TPA 12-0-tetradecanoylphorbol-13-acetate
- CRE CRE, 5'-TGACGTCA-3'
- the present invention is based on the recognition that thiomodified aptamers may be designed, isolated and used to manipulate transcription factors such as NFKB and AP-1 to interdict the pathogenetic sequence, or even boost early protective innate immune responses (Figure 1).
- transcription factors such as NFKB and AP-1
- Figure 1 To demonstrate the feasibility of using the modified thioaptamers disclosed herein at physiological concentrations, animal model systems were used that models both severe fatal disease and self-limited infection with mild disease.
- a well-recognized and widely used guinea pig model for Lassa Fever uses the New World arenavirus Pichinde (PIC) (Peters et al., 1987) was used and adapted to study pathogenesis by comparing an attenuated variant of PIC (P2) and a closely related virulent variant derived by serial guinea pig passage (P18) (setting et al., 1981).
- PIC New World arenavirus Pichinde
- the present invention was used to modulate induction of CREB, a transcription factor regulated by cyclic AMP (cAMP) signaling.
- cAMP cyclic AMP
- the modified thioaptamers were used to modulate CREB activity and were demonstrated to modify virulent and attenuated Arenavirus infection.
- the CREB protein is also a member of the AP-1 family of transcription factors whose targeting by XBY-S2 has provided protection for animals infected with arenavirus and flavivirus.
- cAMP is a ubiquitous second messenger (Antoni et al., 2000) synthesized in cells by adenylyl cyclases in response to many extra-cellular stimuli.
- the present invention provides a number of advantages due to the use of modified thioaptamers and combinatorial selection methods.
- the present invention provides very high affinity - nM to sum-nM (> monoclonal IgMs and >non-substituted aptamers), target-specific aptamers, demonstrating single protein target binding within cellular extracts.
- the modified thioaptamers have greater resistance to cellular or serum nuclease degradation than normal backbone aptamers, or proteases towards antibodies. Due to the increased nuclease resistance, the aptamers disclosed herein may be packaged to have indefinite shelf-life, ease of storage as lyophilized powders at room temperatures, unlike unmodified RNA or antibodies and are relatively inexpensive to produce.
- compositions disclosed herein allow for high reproducibility in quality control, unlike diasteromeric mixtures for non-stereospecifically produced monothiophosphate aptamers, or protein production of antibodies.
- use of bead- based thioaptamer libraries or library of libraries provides large combinatorial libraries readily selected by multicolor flow cytometry at very high speeds (10 8 /hr).
- the location of protein binding on such a microarray may be detected using well known protein detection methods, e g , fluorescence
- the protein for use with the invention may be protein from a crude extract or even partially purified or isolated, e g , one or more proteins isolated from a gel
- the system and method disclosed herein may further include the use of binding the thioaptamers to beads and sorting the beads to isolate and identify proteins that have specifically bound to the thioaptamers
- the beads when using a thioaptamer library of beads, the beads may be sorted based on protein binding, e g , based on fluorescence labeling of the aptamer and or the protein using a flow-cytometer
- the protein may be from a cell extract, which may even be a cell extract from a virally infected or diseased cell
- the thioaptamers are attached to beads and the beads are substantially protein-free
- the thioaptamers When using a one-bead, one-thioaptamer (ODN) library or even a library of libraries the thioaptamers may be one or more beads that include an [S]-ODN and/or [S 2 ]-ODN combinato ⁇ al libraries
- the ODNs may be single or double stranded and may include
- one or more of the thioaptamers may be a library of aptamers that binds to one or more transcritption factors and includes sequences or sequence motifs for transcription factor binding, e.g., a NF- ⁇ B, a RBP-J ⁇ , an AP-1, an NF IL-6, an SP-1, a GRE, an SRE motif and/or mixtures thereof.
- sequences or sequence motifs for transcription factor binding e.g., a NF- ⁇ B, a RBP-J ⁇ , an AP-1, an NF IL-6, an SP-1, a GRE, an SRE motif and/or mixtures thereof.
- the complex combinatorial library made by a method that includes the steps of synthesizing an aptamer bead library having a first thioaptamer and concatenating to each of the first thioaptamers a second aptamer or thioaptamer suspected of binding to, e.g., a nuclear regulatory factor.
- the first and second thioaptamers may even be suspected of binding the same nuclear regulatory factor or a different nuclear regulatory factor.
- Yet another embodiment of the present invention is a method of identifying a thio-modified therapeutic agent that includes mixing a sample suspected of including a DNA binding protein with a concatenated first and second thioaptamer under binding conditions and isolating the one or more DNA binding proteins that bind specifically to the concatenated aptamers.
- Another embodiment of the present invention is a composition, adjuvant, vaccine and method of modifying an immune response that includes providing a host cell with aptamers that suppress the activity of a nuclear regulatory factor critical for activation of an immune response.
- the immune response may be an innate immune response, a cytotoxic or a helper T cell immune response.
- the thioaptamer modified the immune response by shifting the helper 1-type (Thl) to T helper 2-type (Th2) ratio.
- the immune response that is modified may be to a virus, a bacteria, a fungus, a cancer, a self- antigen, a heterologous antigen, a retrovirus, a hemorraghic virus or a neuropathologic virus, e.g., West
- the immune response that is modified may be modified in vivo, in vitro and/or ex vivo.
- the modification of the immune response may be an increase or decrease of the immune response as measured by, e.g., antibody production, cytotoxic T cell activation, cytokine release, apoptosis, cell proliferation, cell killing, chromium release, nucleic or amino acid uptake or release and other methods known to those skilled in the immunological arts.
- the type of helper T cell response may be modified by providing a host or target cell with one or more thioaptamers that suppress the activity of a nuclear regulatory factor critical for activation of, e.g., a helper T cell response.
- the T cell immune response may be to, e.g., a virus, a bacteria, a fungus, a cancer, a self-antigen, a heterologous antigen, a retrovirus, a hemorraghic virus or even a neuropathologic virus.
- the modification to the immune response may be to a challenge to the innate or the adaptive immune response.
- the helper T cell response may be a T helper 1-type response or a T helper 2-type response.
- Arenaviridae Lassa, Junin, Machupo, Guanarito, and Sabia viruses, which are the causative agents of Lassa fever and Argentine, Venezuelan, and Brazilian hemorrhagic fevers, respectively
- Filoviridae Ebola and Marburg
- Flaviviridae yellow fever, Omsk hemorrhagic fever, and Kyasanur Forest disease viruses
- Bunyaviridae Rift Valley fever (RFV), Congo-Crimean hemorrhagic fever.
- RSV Ring Valley fever
- Another target viral family includes Hantaviruses.
- the thioaptamers of the present invention may be an adjuvant that forms part of a vaccine, such as a composition that includes one or more partially thio-modified or even concatenated aptamers that modulate an immune response.
- the thioaptamer adjuvant may also include at least one antigen.
- the antigens for innate immune response activation may be a pathogen-associated molecular pattern antigen, e.g., a CpG molecule, a saccharide, a lectin, a polysaccharide and the like.
- the adjuvant thioaptamer may include sequences for specific recognition and binding to nuclear regulatory factors, e.g., NF-AT, NF-KB, RBP-JK, AP-1, NF IL-6, SP-1, GRE and SRE.
- nuclear regulatory factors e.g., NF-AT, NF-KB, RBP-JK, AP-1, NF IL-6, SP-1, GRE and SRE.
- partially thioaptamers include one or more of the aptamers of SEQ ID NOS.: 2, 3, 4, 5, 6, 7, 8 and 9.
- the thioaptamer may an adjuvant that includes one or more partially thioaptamers that bind to, e.g., a DNA binding protein and modulate an immune response, e.g., an innate or an adaptive immune response.
- the adjuvant may be provided with a physiologically acceptable aqueous vehicle, in a lyophilized, a particulate or even a dissolved form with or without an antigen, e.g., the antigen described hereinabove.
- Yet another embodiment of the present invention is a method for modifying an immune response that includes administering a composition that includes an antigen and one or more partially thio-modified aptamers or thioaptamers.
- the modifications to the immune response include, e.g., activation or deactivation of the innate immune response and/or modifications to the type of immune response mounted (humoral versus cell-based) such as a change in the profile of helper T cell involved with or "lead” the immune response
- the composition may also include cytokines, e g , ⁇ nterleuk ⁇ n-1 (IL-1), ⁇ nterleuk ⁇ n-2 (IL-2), ⁇ nterleuk ⁇ n-3 (IL-3), ⁇ nterleukm-4 (IL-4), ⁇ nterleuk ⁇ n-5 (IL-5), ⁇ nterleuk ⁇ n-6 (IL-6), ⁇ nterleuk ⁇ n-7 (IL-7), ⁇ nterleuk ⁇ n-8 (IL-8), ⁇ nterleuk ⁇ n-10
- the thioaptamer (thioaptamer) and an antigen may be provided in dry form or even be disposed in a vehicle suitable for oral, intramuscular, subcutaneous, intravenous or parenteral administration, e.g., in a sterile saline solution.
- the partially thioaptamer may be specific for AP-1, NF- ⁇ B, NF IL-6, or combinations thereof.
- Figure 7 is a gel that shows that XBY-S2 eliminates API DNA binding activities in macrophages treated with liposomes with and without the indicated aptamers for 24 hours, wherein the nuclear extracts were analyzed by electrophoretic mobility shift assay (EMSA) with the AP-1 and NF- ⁇ B oligonucleotide probes;
- ESA electrophoretic mobility shift assay
- Figure 11 is a graph that shows survival curves of guinea pigs with thioaptamers for infection by arenavirus
- Figure 12 is a graph that shows survival curves following West Nile Virus infection in guinea pigs treated with the NF- ⁇ B aptamer XBY-6, the AP-1 aptamer XBY-S2, or the liposome vehicle of animals infected by injection with lethal doses of West Nile Virus;
- the modified nucleotide aptamer can include one or more phosphorothioate or phosphordithioate linkages selected from dATP( ⁇ S), dTTP( ⁇ S), dCTP( ⁇ S) and dGTP( ⁇ S), dATP( ⁇ S 2 ), dTTP( ⁇ S 2 ), dCTP( ⁇ S 2 ) and dGTP( ⁇ S 2 ).
- no more than three adjacent phosphate sites of the modified nucleotide aptamer are replaced with phosphorothioate groups.
- thioaptamers may be obtained by adding bases enzymatically using a mix of four nucleotides, wherein one or more of the nucleotides is a mix of unmodified and thiophosphate- modified nucleotides, to form a partially thiophosphate-modified thioaptamer library.
- thioaptamers these are made by adding bases to an oligonucleotide wherein a portion of the phosphate groups are thiophosphate-modified nucleotides, and where no more than three of the four different nucleotides are substituted on the 5'-phosphate positions by 5'-thiophosphates in each synthesized oligonucleotide are thiophosphate-modified nucleotides.
- a dosage unit for use of the aptamers and partially thioaptamers of the present invention may be a single compound or mixtures thereof with other compounds, e.g., a potentiator.
- the compounds may be mixed together, form ionic or even covalent bonds.
- the aptamers and partially thioaptamers of the present invention may be administered in oral, intravenous (bolus or infusion), intraperitoneal, subcutaneous, or intramuscular form, all using dosage forms well known to those of ordinary skill in the pharmaceutical arts.
- different dosage forms e.g., tablets, capsules, pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsions may be used to provide the aptamers and partially thioaptamers of the present invention to a patient in need of therapy that includes the aptamers and partially thioaptamers.
- the aptamers and partially thioaptamers may also be administered as any one of known salt forms.
- Aptamers and partially thioaptamers is typically administered in admixture with suitable pharmaceutical salts, buffers, diluents, extenders, excipients and/or carriers (collectively referred to herein as a pharmaceutically acceptable carrier or carrier materials) selected based on the intended form of administration and as consistent with conventional pharmaceutical practices.
- a pharmaceutically acceptable carrier or carrier materials selected based on the intended form of administration and as consistent with conventional pharmaceutical practices.
- the aptamers and partially thioaptamers may be formulated to provide, e.g., maximum and/or consistent dosing for the particular form for oral, rectal, topical, intravenous injection or parenteral administration. While the aptamers and partially thioaptamers may be administered alone, it will generally be provided in a stable salt form mixed with a pharmaceutically acceptable carrier.
- the carrier may be solid or liquid, depending on the type and/or location of administration selected.
- the aptamers and partially thioaptamers may be administered in the form of liposome delivery systems, e.g., small unilamellar vesicles, large unilamallar vesicles, and multilamellar vesicles, whether charged or uncharged.
- Liposomes may include one or more: phospholipids (e.g., cholesterol), stearylamine and/or phosphatidylcholines, mixtures thereof, and the like.
- the oral drug components may be combined with any oral, non-toxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water, and the like.
- suitable liquid dosage forms include solutions or suspensions in water, pharmaceutically acceptable fats and oils, alcohols or other organic solvents, including esters, emulsions, syrups or elixirs, suspensions, solutions and/or suspensions reconstituted from non-effervescent granules and effervescent preparations reconstituted from effervescent granules.
- Such liquid dosage forms may contain, for example, suitable solvents, preservatives, emulsifying agents, suspending agents, diluents, sweeteners, thickeners, and melting agents, mixtures thereof, and the like.
- Citric acid and its salts and sodium EDTA may also be included to increase stability.
- parenteral solutions may include pharmaceutically acceptable preservatives, e.g., benzalkonium chloride, methyl- or propyl-paraben, and/or chlorobutanol. Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, Mack Publishing Company, a standard reference text in this field, relevant portions incorporated herein by reference.
- Capsules may be prepared by filling standard two-piece hard gelatin capsules each with 10 to 500 milligrams of powdered active ingredient, 5 to 150 milligrams of lactose, 5 to 50 milligrams of cellulose and 6 milligrams magnesium stearate.
- Soft Gelatin Capsules A mixture of active ingredient is dissolved in a digestible oil such as soybean oil, cottonseed oil or olive oil. The active ingredient is prepared and injected by using a positive displacement pump into gelatin to form soft gelatin capsules containing, e.g., 100-500 milligrams of the active ingredient. The capsules are washed and dried.
- Tablets A large number of tablets are prepared by conventional procedures so that the dosage unit was 100-500 milligrams of active ingredient, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 50-275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase palatability or delay absorption.
- Effervescent tablets To provide an effervescent tablet appropriate amounts of, e.g., monosodium citrate and sodium bicarbonate, are blended together and then roller compacted, in the absence of water, to form flakes that are then crushed to give granulates. The granulates are then combined with the active ingredient, drug and/or salt thereof, conventional beading or filling agents and, optionally, sweeteners, flavors and lubricants.
- active ingredient, drug and/or salt thereof conventional beading or filling agents and, optionally, sweeteners, flavors and lubricants.
- aqueous suspension is prepared for oral administration so that each 5 ml contain 100 mg of finely divided active ingredient, 200 mg of sodium carboxymethyl cellulose, 5 mg of sodium benzoate, 1.0 g of sorbitol solution, U.S. P., and 0.025 ml of vanillin.
- the aptamers and partially thioaptamers and, optionally, one or more potentiators may be mixed with a pharmaceutically acceptable carrier.
- the carrier may be a solid or liquid and the type is generally chosen based on the type of administration being used.
- the active agent may be coadministered in the form of a tablet, capsule, liposome, as an agglomerated powder, in a liquid form or as a suppository.
- the present invention includes vaccines for both active and passive immunization.
- Immunogenic compositions suitable for use as a vaccine, include the modified thioaptamers of the present invention.
- the thioaptamers are prepared in a manner disclosed herein.
- the vaccines disclosed herein are not the antigenic material, that is, they are not intended to cause an immune response, but rather, are include either alone or in combination with an antigen to "drive” or modify an immune response by altering the activity of nuclear binding proteins, including, e.g.: NF-ATs, AP-ls, NF-IL6, NF- ⁇ B, HIV reverse transcriptase, Venezuelan Equine Encephalitis nucleocapsid (using an RNA thioaptamer), HepC IRES nucleic acid, protein(s) involved in CpG-induced "innate immunity,” and the like.
- nuclear binding proteins including, e.g.: NF-ATs, AP-ls, NF-IL6, NF- ⁇ B, HIV reverse transcriptase, Venezuelan Equine Encephalitis nucleocapsid (using an RNA thioaptamer), HepC IRES nucleic acid, protein(s) involved in CpG-induced "innate immunity,” and the like.
- the active immunogenic ingredient is often mixed with excipients that are pharmaceutically acceptable and compatible with the active ingredient.
- excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof.
- the vaccine may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents, or adjuvants which enhance the effectiveness of the vaccines.
- parvum or endotoxins or lipopolysaccharide components of gram-negative bacteria emulsion in physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed.
- physiologically acceptable oil vehicles such as mannide mono-oleate (Aracel A) or emulsion with 20 percent solution of a perfluorocarbon (Fluosol-DA) used as a block substitute may also be employed.
- the thioaptamer and the methods disclosed herein may be used to manipulate Thl:Th2 ratios in a variety of clinical situations.
- a thioaptamer may be provided that inhibits Th2 activation, which may be useful in allergic diseases, malignancies and infectious diseases.
- the thioaptamer may be used to enhance Th2 activation for treatment of autoimmune diseases and/or to improve organ transplantation.
- the present inventors recognized that it is not possible to simply replace thiophosphates in a sequence that was selected for binding with a normal phosphate ester backbone oligonucleotide. Simple substitution was not practicable because the thiophosphates can significantly decrease (or increase) the specificity and or affinity of the selected ligand for the target. It was also recognized that thiosubstitution leads to a dramatic change in the structure of the aptamer and hence alters its overall binding affinity.
- the sequences that were thioselected according to the present methodology, using as examples of DNA binding proteins AP-1, NF-IL6 and NF- ⁇ B, were different from those obtained by normal phosphate ester combinatorial selection.
- the present invention takes advantage of the "stickiness" of thio- and dithio-phosphate ODN agents to enhance the affinity and specificity to a target molecule.
- the method of selection concurrently controls and optimizes the total number of thiolated phosphates to decrease non-specific binding to non-target proteins and to enhance only the specific favorable interactions with the target.
- the present invention permits control over phosphates that are to be thio-substituted in a specific DNA sequence, thereby permitting the selective development of aptamers that have the combined attributes of affinity, specificity and nuclease resistance.
- a method of post-selection aptamer modification in which the therapeutic potential of the aptamer is improved by selective substitution of modified nucleotides into the aptamer oligonucleotide sequence.
- An isolated and purified target binding aptamer is identified and the nucleotide base sequence determined.
- Modified achiral nucleotides are substituted for one or more selected nucleotides in the sequence.
- the substitution is obtained by chemical synthesis using dithiophosphate nucleotides.
- the resulting aptamers have the same nucleotide base sequence as the original aptamer but, by virtue of the inclusion of modified nucleotides into selected locations in the sequences, improved nuclease resistance and affinity is obtained.
- Phosphorodithioate analogs have been synthesized to produce an important class of sulfur-containing ohgonucleotides, the dithiophosphate S 2 -ODNs.
- These dithioates include an internucleotide phosphodiester group with sulfur substituted for both nonlinking phosphoryl oxygens, so they are both isosteric and isopolar with the normal phosphodiester link, and are also highly nuclease resistant.
- One group showed highly effective protection of the dithioate against degradation by endogenous nucleases after 58% backbone modification.
- the S 2 -ODNs in contrast to the phosphoramidite- synthesized monothiophosphate (S-ODNs), are achiral about the dithiophosphate center, so problems associated with diastereomeric mixtures (Lebedev & Wickstrom, 1996) are completely avoided.
- the S 2 - ODNs and the S-ODNs are taken up efficiently by cells, especially if encapsulated in liposomes.
- thiosubstitution can also perturb the structure of the duplex (Cho et al., 1993) (Volk et al, 2002) although monothiophosphates substituted in the DNA strand of DNA/RNA hybrids do not appear to have dramatically altered duplex structures (Bachelin et al., 1998; Gonzalez et al., 1995).
- the present invention uses sequence-based, structure-based and combinatorial methods to identify both sequences and thiophosphate substitution patterns to develop thioaptamers that retained the highest specificity and affinity in binding to target proteins. The use of partial thiophosphate substitution resulted in aptamer that were more stable in vivo.
- thiophosphate aptamers may be used with the present invention.
- a recent advance in combinatorial chemistry has been the ability to construct and screen large random sequence nucleic acid libraries for affinity to proteins or other targets (Ekland et al., 1995; Gold et al., 1997; Tian et al., 1995).
- the aptamer nucleic acid libraries are usually selected by incubating the target (protein, nucleic acid or small molecule) with the library and then separating the non-binding species from the bound. The bound fractions may then be amplified using the polymerase chain reaction (PCR) and subsequently reincubated with the target in a second round of screening.
- PCR polymerase chain reaction
- agents selected from combinatorial RNA and DNA libraries have previously always had normal phosphate ester backbones, and so would generally be unsuitable as drugs or diagnostics agents that are exposed to serum or cell supernatants because of their nuclease susceptibility.
- the effect of substitution of nuclease-resistant thiophosphates cannot be predicted, since the sulfur substitution can lead to significantly decreased (or increased) binding to a specific protein (Milligan & Uhlenbeck, 1989).
- the present invention have described the combinatorial selection of phosphorothioate oligonucleotide aptamers from random or high-sequence-diversity libraries, based on tight binding to the target (e.g. a protein or nucleic acid) of interest, relevant portions of which are incorporated herein by reference.
- target e.g. a protein or nucleic acid
- An in vitro selection approach for RNA thioaptamers has also been described Ellington and co-workers (Jhaveri et al., 1998).
- a combinatorial library was created by PCR, using an appropriate dNTP( ⁇ S) in the Taq polymerization step.
- a combinatorial thiophosphate duplex and single stranded (ss) libraries was screened successfully for binding to a number of different protein and nucleic acid targets, including NF-IL6, NF- ⁇ B, HIV reverse transcriptase, Venezuelan Equine Encephalitis nucleocapsid (using an RNA thioaptamer), HepC IRES nucleic acid, and others, including a protein involved in CpG-induced "innate immunity.”
- a filter binding method was used that was modified to minimize non-specific binding of the S-ODNs to the nitrocellulose filters.
- the wild-type CK-1 duplex sequence contains 3 tandem repeats of a 14-mer NF-KB consensus-like sequence (5' -CCA GGA GAT TCC ACC CAG GAG ATT CCA CCC AGG AGA TTC CAC 3') (SEQ ID NO.: 11).
- S-ODN CK-1 monothioate aptamers were made because it was unlikely that the phosphodiester form is appropriate for therapeutics or diagnostics because of its short half-life in cells, cell extracts and serum. The phosphorothioate and dithioate internucleoside modifications are therefore needed.
- the CK-1 aptamer inhibited p65/p65 and p50/p50 equally; confirming that S-ODNs with large numbers of phosphorothioate linkages are "sticky" and tend to bind proteins non-specifically.
- the present inventors also found that if the number of phosphorothioate linkages is decreased to only 2-4, specificity can be restored, but binding is not enhanced. Therefore, the original publications described only the specificity of the phosphodiester ohgonucleotides and did not address the problem of altered specificity of the phosphorothioates.
- Binding studies were conducted using a chemiluminescent EMSA, which uses a biotinylated thioaptamer.
- the biotinylated thioaptamer binds tightly to p50; the sequences are different from those obtained for in vitro combinatorial selection against p65 homodimers (Table 2).
- the chemically synthesized phosphorothioate aptamers are a diastereomeric mixture of both Rp and Sp configurations.
- S 2 -ODN CK-14 dithioate aptamers were also isolated.
- the CK-14 14-mer duplex was also synthesized with some strategically placed dithioate linkages (both of the non-bridging oxygens are replaced by sulfurs).
- strategic dithioate linkage ODNs have exhibit significant differences, as they have altered binding specificity, and lack the extreme "stickiness" of the fully thioated aptamer. With an increasing number of dithioate substitutions in the same sequence, binding by the S 2 -ODN increases dramatically (data not shown).
- the band did not co-migrate with either the p50/p50 or p50/p65 bands, but the change in the altered chemical structure changes the mobility of the ODN. Only one major band is seen, however, even though the lysate contains at least two major distinguishable NF- ⁇ B complexes (p50 homodimers and p50/p65 heterodimers).
- Phosphorodithioate and phosphorothioate aptamers via split synthesis combinatorial selection.
- the identification of specific S-ODN and S 2 -ODN thioaptamers that bind proteins based upon in vitro combinatorial selection methods is limited to substrates only accepted by polymerases required for reamplification of selected libraries by the polymerase chain reaction (PCR).
- PCR polymerase chain reaction
- Another disadvantage of using the polymerization of substituted nucleoside 5'-triphosphates into ODN aptamers are the restrictions on the choice of P-chirality by the enzymatic stereospecificity.
- a one-bead one-oligonucleotide (one-ODN) (e.g., O-ODN, S- ODN, S 2 -ODN, both DNA or RNA) may be used in conjunction with combinatorial library selection methodology used to identifying a specific oligonucleotide aptamer that binds to specific proteins or other molecules (Yang, et al., 2002; Gorenstein, et al., U.S. patent applied).
- the method may use S 2 -ODN reagents with sulfurs replacing both of the non-bridging phosphate oxygens that are isosteric and isopolar with the normal phosphorodiester and are particularly advantageous for binding and screening.
- S 2 -ODNs are achiral about the dithiophosphate center, which eliminated problems associated with diastereomeric mixtures generally obtained for the chemically synthesized S-ODN.
- the dsDNA thioaptamer library beads were screened for the ability to bind the NF- ⁇ B p50/p50 dimer labeled with the Alexa Fluor 488 dye (Molecular Probes). After initial binding of protein, the beads were thoroughly washed with PBS with 0.1% Tween 20 to minimize nonspecific binding. Typically, a few positive beads were intensely stained when viewed by fluorescence, while the majority of the beads remained unstained as (data not shown). With the aid of a micropipette coupled to a micromanipulator, the intensely stained beads were retrieved. Only highly positive beads from several thousand were found using this method. As described below, multicolor flow cytometry and cell/bead sorting was used to automate the selection process to select the tightest binding thioaptamer-protein complexes.
- the S- ODN, 5'-CtGTGAGtCGACTgAtGaCGGt-3' (SEQ ID NO.: 7) (small letters represent location of 3'- mono thiophosphates) was synthesized independently on the non-cleavable linker bead support, hybridized with its complementary ODN and then mixed again with the p50/p50 protein labeled with the Alexa Fluor 488 dye.
- the fluorescence intensity of all of the beads viewed under the fluorescence microscope was qualitatively similar to the intensity of the selected bead containing this sequence within the combinatorial library.
- the beads were screened against a target protein labeled with a fluorescent dye, the beads have also been screened directly against cell extracts as well.
- the binding of the NF- ⁇ B to a specific sequence can be detected using a primary anti-NF- ⁇ B antibody such as anti-P50 (Rabbit IgG antibody, Santa Cruz Biotechnology, Inc.) followed by a secondary antibody conjugated with Alexa Fluor 488 (goat anti-rabbit IgG from Molecular Probes).
- Beads that included the XBY-6 oligonucleotide were screened against WI- 38 VA13, an SV40 virus-transformed human fibroblastic cell line extract by similar fluorescent microscopy.
- Flow cytometry sorting of thioaptamer bead-based library The present inventors have also demonstrated the successful application of high throughput/multi-color flow cytometry and bead sorting to screen aptamer bead libraries for those beads which bind to, e.g., a target protein (Gorenstein, et al., patent pending, 2002). Modifications were made to a custom-built flow cytometer to make it more amenable to bead identification and isolation. For example, bead fluorescence and forward scatter were the two parameters chosen for real-time characterization of each aptamer bead passing the first sort point of the custom-built flow cytometer/sorter. Other scanning and sorting parameters may be used to select, isolate, view, designate, characeterize, etc. the beads through a flow cytometer.
- "positive" beads intain thioaptamer-bound target protein, the target protein was fluorescent-labelled with Alexa 488 dye) were easily sorted from negative beads.
- Flow cytometry may be used to replace, e.g., visual fluorescence microscope identification of beads containing bound target protein and the need to isolate the individual "positive” beads with the micromanipulator described previously.
- the flow-sorted "positive” beads can then be subjected to, e.g., one-bead PCR to identify the thioaptamer that binds the target protein.
- Fluorescence sorting was also used to demonstrate the use of the one-bead, one-ODN:protein system using dual color sorting.
- the Ig ⁇ B dsDNA consensus sequences were immobilized onto 15-20 micron polystyrene microspheres.
- the DNA bound beads were then incubated with purified p50 and p65 proteins, respectively.
- DNA transcription factor complexes were detected with primary antibodies specific for the p50 and p65 proteins followed by an additional incubation with Alexa 488- conjugated secondary antibody for p50 and PE- conjugated secondary antibody for p65.
- the beads were viewed by fluorescent microscopy and then analyzed on the MCU's HiReCS system.
- TLR9 acts as a receptor for unmethylated CpG dinucleotides in the bacterial DNA.
- Human and mouse TLR9 share an overall amino-acid identity of 75.5%. TLR9 is highly expressed in spleen (Krieg, 2002).
- the immunostimulatory properties of bacterial DNA appears to be related to short six base sequences called CpG motifs that have the general structure of two 5' purines, an unmethylated CpG motif, and two 3' pyrimidines (Krieg, 2002). Though such sequences rarely appear in mammalian DNA due to CpG suppression and methylation of cytosine nucleotides, they are relatively abundant in bacterial DNA, occurring at the expected frequency (1 in 16) and in unmethylated form.
- pathogenic Arenaviruses appear to block or modify immunoregulatory cell signaling pathways (Peters & Zaki, 2002, Solomon and Vaughn, 2002; Fennewald et al., 2002).
- Using the present invention it was possible to disrupt Arenavirus and Flavivirus cell signals that contribute to immune evasion and pathogenesis.
- thioaptamers it was demonstrated that the thio-modified aptamers of the present invention could be used to counteract viral induced cellular perturbations and protect the infected host.
- viruses have developed ingenious strategies to counteract the host defenses that normally control viral replication and spread. Similarly, viral strategies modify the cellular environment to promote viral macromolecular synthesis and viral replication. This highly ordered interation often has the unfortunate consequence of inducing disease in the host.
- Viruses have evolved mechanisms to interfere with major histocompatibility complex antigen presentation, block apoptosis, disrupt complement cascades and modulate multiple cytokine networks (Lalani & McFadden, 1999; Ploegh, 1998). Viruses have targeted cell-signaling pathways involved in cytokine and chemokine signaling, the regulation of apoptosis, and the cell cycle.
- Influencing key transcription factors that regulate pro or anti-inflammatory cytokines is an efficient means by which viruses could cripple multiple immune responses (Powell et al, 1996; Tait et al, 2000).
- the strategies employed by the smaller, less genetically complex viruses are equally elegant, and often even more of an enigma.
- Pichinde infection of guinea pigs is particularly suited to studies on the immunomodulation by virus infection.
- the differential effect of virus infection was identified as including a profound effect on the transcription factors NF- ⁇ B and RBP-J ⁇ .
- FIG. 2 is a graph that shows that polyl/C is an effective inducer of the proinflammatory cytokine TNF- ⁇ .
- Infection with P2 and PI 8 also alter the expression of this and other inflammatory cytokines.
- P2 and PI 8 induced equally cytokines such as IL-6; which are moderately different in their induction of TNF- ⁇ and substantially different in IL-12 induction ( Figure 3).
- XBY-6 SEQ ID NO.: 1 targeting NF- ⁇ B p50 homodimers and XBY-S2 targeting AP-1, both with six dithio residues.
- XBY-S2 SEQ ID NO.: 2 is demonstrated to bind specifically to AP-1 proteins in pre-B cell nuclear extracts (70Z/3) and to human recombinant c-jun protein dimers (AP-1).
- supershift analyses indicate that XBY-S2 binds to several members of the AP-1 protein family including JunD, CREB and possibly ATF2, and c-Jun.
- the XBY-6 thioaptamer binds specifically to the NF- ⁇ B p50 (or pl05) homodimer (Figure 6). Macrophage cultures were treated with XBY-S2 and XBY-6 and nuclear extracts were produced to assay the effects of these thioaptamers on the DNA binding activities of the transcription factors to which they are targeted. In Figure 7, macrophage cultures were treated with liposomes, and liposome containing the indicated thioaptamers overnight and nuclear extracts produced and assayed using the indicated ohgonucleotides. The XBY-S2 thioaptamer efficiently eliminated transcription factor binding to the AP-1 oligonucleotide. In contrast, treatment with XBY-6 resulted in an increase in the NF- ⁇ B DNA binding activity.
- XBY-6 thioaptamer and Pichinde virus Based on the preliminary results obtained with XBY-6 thioaptamer and Pichinde virus, it was determined if XBY-6 or XBY-S2 would have any antiviral activity against flaviviruses.
- the thioaptamers (10 ⁇ g) were delivered IP in Tfx50 liposomes and administered in two doses (one day before and 90 minutes before virus challenge).
- mice of which 6 would be sampled
- virus challenge 100 LD 50 virus.
- Table 6 the initial results were reproducible. Both control groups (PBS and liposomes) succumbed to challenge with WN virus while the thioaptamer-treated mice survived and remained healthy.
- the proportion of mice treated with XBY-S2 thioaptamer who survived challenge was the same in both studies (80%) while XBY-6 treatment protected 50% of mice in the second study as compared to 80% of mice in the first study. These differences were not statistically significant given the small sample sizes.
- the thioaptamer may be inducing localized interferon (or other mediators of the innate immune response) that inhibits replication of the virus since the thioaptamer includes double-stranded DNA while double-stranded RNA is known to be an efficient inducer of interferon.
- Study 2 Female 3-4 week-old NIH Swiss mice were given aptamers at one day before and 90 minutes before administration of 100 LD50 WN virus strain USA99b by the ip route. Group # surviving [%] AST(days ⁇ SD) PBS only 0/10 [0] 8.3 ⁇ 0.8 Liposomes only 0/10 [0] 7.7 ⁇ 1.1 XBY-S2 8/10 [80] 8.5+0.7 XBY-6 5/10 [50] 8.0 ⁇ 0.7
- Figure 10 is a graph that shows survival curves following Pichinde PI 8 infection in guinea pigs treated with the NF-KB aptamer, XBY-6, the scrambled control, B92, or vehicle, MT, of animals infected by injection of 1000 pfu of Pichinde P18 at day 0, treatment consisted of intraperitoneal injections at days 0, l and 2;
- duplex aptamers were the dithioate 14-mers XBY-6 (C12-XBY-6), the normal phosphate backbone 22-mer NF- ⁇ B binding site with the C12 5'-amino linker (C12-Ig ⁇ B) or a non-specific, non-covalently linked duplex (polydldC) as a control. These aptamers were spotted individually onto spots of a preactivated ProteinChip Array (PS20) in 2 ⁇ l of 25 mM NaHC ⁇ 3 (pH 9) and incubated overnight at room temperature and high humidity.
- PS20 ProteinChip Array
- Figure 14 shows that the XBY-6 thioaptamer can also capture recombinant p50 (MW ⁇ 46,200) on gel beads to which the 5'amino-C12 linked XBY-6 is coupled to 20 ul (1: 1) AminoLink® Plus Coupling gel (Pierce, Immunoprecipitation kit, cat # 45335).
- p50 MW ⁇ 46,200
- AminoLink® Plus Coupling gel Pierce, Immunoprecipitation kit, cat # 45335.
- 3 ⁇ g of C12-XBY-6 was coupled overnight at 4°C following the kit protocol.
- 6 ⁇ g of p50 in IX EMSA buffer with polydldC was added to the gel and incubated for 2 hrs with shaking at room temperature. The gel was washed to remove nonspecifically bound proteins, followed by one quick rinse with water.
- Protein bound to the gel was extracted with 5 ⁇ l of organic solvent (50% AcN and 0.01% TFA) with shaking for 20 min. All of the extracts were spotted onto NP20 ProteinChips, dried, followed by addition of saturated SPA and read on the Ciphergen PBSII MS (top two spectra). After extraction, 1 ⁇ l of the gel was loaded onto NP20 chip (bottom two spectra). Proteins still bound to the gel was analyzed using saturated SPA on the PBSII. Once again it was found that p50 can be identified by SELDI, both in the extract and retained directly on the beads.
- Figure 15 shows the capture of nuclear extracts onto Ciphergen's PS20 ProteinChip Arrays: Either 0.5 ⁇ g of C12-XBY-6, 0.25 pm of C12-Ig ⁇ B or 0.5 ⁇ g of poly dldC were incubated on PS20 chip overnight. The chips were blocked with 7 mg/ml BSA in PBS/0.1% Tween-20. Following blocking, 49 ⁇ g of nuclear extract in optimized EMSA buffer were incubated on each spot for 2 hr with shaking. Each spot was washed with PBS/0.1% Triton three times, followed by one quick wash with water. Proteins bound on each spot were analyzed using saturated SPA on the PBSII. These results indicate that a protein was bound with a MW -105,591, which may represent pl05, the precursor to p50 or the p50/p50 homodimer.
- thioaptamer combinatorial libraries were created that cover appropriate sequence space relative to the targeted protein.
- duplex thioaptamers were create that have a significant population of sequences similar to the consensus sequence.
- the complexity of the library can be as large as 10 14 different sequences and thus can cover all sequence space for a small ( ⁇ 22 nt) duplex.
- complexity is limited to the number of different beads - 10 6 -10 8 , depending on their size.
- a bead- based library of libraries of thioaptamers is made in which as many as 10 6 different thioaptamers are attached to a single bead and thus have a total complexity of as many as 10 12 -10 14 sequences in the library of library.
- a library of libraries was prepared on a 1 ⁇ mole scale of polystyrene beads (60-70 ⁇ m).
- the downstream and upstream primers 5'-d(GGATCCGGTGGTCTG)-3' (SEQ ID NO.: 26) and 5'-d(CCTACTCGCGAATTC)-3' (SEQ ID NO.: 27) were synthesized in parallel on a two-column DNA synthesizer (Expedite 8909, Applied Biosystems). Following the 5'-primer, the sequences programmed on the synthesizer for the combinatorial library were 5'-AT*GN*GA*AT*TT*NC*CA 3' (SEQ ID NO.: 28) on column 1 and 5'- GG*AG*NG*CN*CA*GG*AC -3' (SEQ ID NO.: 29) on column 2.
- the 3'-primer sequence completed the 44-mer programmed on the synthesizer.
- a "split and pool” was used at each position indicated by an asterisk in order to synthesize the combinatorial region for the library of libraries.
- the letter N indicates a mixture of four bases (A, C, G and T). Five of the beads were randomly selected from the library and "one bead one PCR" was run, cloned and sequenced. The results listed below indicated the successful construction of the library of libraries.
- E45-2-2 5'-GG AG GA CA TT GC AC-3' (SEQ ID NO.: 31)
- E45-2-4 5'-GG AG GA CC TT CC AC-3' (SEQ ID NO.: 32)
- E45-2-5 5'-GG AG GA CC TT GC AC-3' (SEQ ID NO.: 33)
- E45-2-11 5'-GG AG GA CN TT TC AC-3' (SEQ ID NO.: 34)
- E45-2-12 5'-GG AG GA CC TT TC AC-3' (SEQ ID NO.: 35)
- E45-3-1 5'-GG GA TG GT CA GG AC-3' (SEQ ID NO.: 36)
- E45-3-3 5'-GG GC GG AT CA GG AC-3' (SEQ ID NO.: 37)
- E45-3-5 5'-GG GA AG AT CA GG AC-3' (SEQ ID NO.: 38)
- E45-3-6 5'-GG GG TG AT CA GG AC-3' (SEQ ID NO.: 39)
- E45-6-1 5'-GG AG CG GT GT CC AC-3' (SEQ ID NO.: 41)
- E45-6-3 5'-GG AG CG GT TT GC CA-3' (SEQ ID NO.: 43)
- E45-6-10 5'-GG AG CG AT TT CC CA-3' (SEQ ID NO.: 44)
- E45-7-2 5'-AT AG NG CC CA GG AC-3' (SEQ ID NO.: 47)
- E45-7-5 5'-AT AG GG CG CA GG AC-3' (SEQ ID NO.: 48)
- E45-8-2 5'-GG AG AG CA CA TC AC-3' (SEQ ID NO.: 50)
- E45-8-4 5'-GG AG CG CG CA GC AC-3' (SEQ ID NO.: 52)
- E45-8-5 5'-GG AG GG CT CA GC AC-3' (SEQ ID NO.: 53)
- E45-8-6 5'-GG AG AG CA CA AC AC-3' (SEQ ID NO.: 54)
- E45-8-10 5'-GG AG CG CG CA TC AC-3' (SEQ ID NO.: 55)
- High quality one-bead one-oligo libraries were contracted by join two pieces of DNA based on an enzymatic ligation reaction or using highly active phosphorothioate towards 5'-iodo groups on the ODN.
- Standard phosphoramidite chemistry was used for synthesis of 5' monophosphate ODN (5'- P(o)CCAGGAGATTCCAC-GGATCCGGTGGTCTGT-bead) (SEQ ID NO.: 57).
- the fully protected ODN with the non-cleavable linker beads were treated with concentrated ammonia at 37°C for 21 hours to remove the protecting groups while allowing the ODN to remain attached to the beads.
- a selected single bead was mixed with the following components: 3 ⁇ l of 40 ⁇ M 15 mer oligonucleotide (5'- CCTACTCGCGAATTC-3', (SEQ ID NO.: 58) 3 ⁇ l of 10 X ligation buffer, 3 ⁇ l of DMSO, 2 ⁇ l of T4 RNA ligase and 19 ⁇ l of ddH 2 0.
- the reaction was performed at 5 °C for 17 hrs. The supernatant was removed carefully and washed with water.
- the single bead PCR reaction was run under established conditions. The PCR products were analyzed on a 15% native polyacrylamide gel.
- the PCR product was cloned using the TA Cloning procedure (Invitrogen) and sequenced on an ABI Prism 310 Genetic Analyzer (Applied Biosystems).
- the desired sequence 5'-CCTACTCGCGAATTC-
- the ligation reaction allows longer random regions of aptamers to be synthesized on the beads with higher yield since a primer region does not have to be stepwise synthesized onto the bead sequence.
- the beads were screened for the ability to bind the appropriate protein (such as the various NF- ⁇ B dimers or API dimers) labeled with the Alexa Fluor 488 dye (Molecular Probes) or by binding fluorophor labeled antibodies as previously described.
- the beads are sorted using a multicolor flow cytometry and cell/bead sorting to visualize and sort the protein-bound thioaptamer beads and select the tightest binding thioaptamer-protein complexes as shown in Figure 6.
- the most intensely stained beads will be retrieved.
- the inventors concentrated on the NFKB and AP-1 dimers, but these methods may be applied by to other proteins involved in the immune response.
- Multicolor flow cytometry was capable of sorting at speeds of 10 8 beads per hour or viewed in terms of assays for thioaptamers binding to target proteins, 10 8 assays per hour.
- High throughput sorting (HTS) of homo- and heterodimers to thioaptamers by multi-color flow cytometry using multi-color flow cytometry HTS may be used to select thioaptamers that bind preferentially to heterodimers of proteins.
- one monomer is tagged fluorescently (A) with a dye (cy3 for example) and a different monomer (B) with another dye (cy5 for example). Both proteins are mixed together and allowed to bind to the bead thioaptamer library.
- two-color flow cytometry is used to compare cy3/cy5 color levels of each bead.
- beads that have high cy3 levels and low cy5 levels are selected. Conversely, high cy5/low cy3 indicates a thioaptamer sequence with selectivity for the B.B dimer. For heterodimers, beads are selected for cy3/cy5 levels close to 1.
- SELDI MS may be used to determine which proteins have been bound to selected combinatory thioaptamer beads and also used with single bead PCR to identify which bead(s) in the combinatorial library have bound to protein(s).
- More than 2 dyes and multi-color flow cytometry may be used to select various multimers.
- NF- KB at least 3 of the 5 different monomeric forms of the protein are combined, each with a different fluorphor and use 3-color flow cytometry to select thioaptamers that have high affinity and selectivity to homodimers A.A, B.B, CC and various heterodimeric forms from the libraries.
- detectable markers e.g., fluorochromes
- 5-color flow cytometry may be used.
- Sequencing may also be performed directly on the bead.
- Each individually selected bead is washed thoroughly with 8 M urea (pH 7.2) to remove the protein and directly used for "one-bead one-PCR" amplification using the 5' and 3' end primers (Yang, et al. 2002).
- the PCR products are TA cloned and sequenced as previously described to create hybrid thioaptamers with normal phosphate, monothiophosphate, and dithiophosphate mixed backbones as well, keeping the total thiophosphate backbone below 80% to minimize "non-specific" sticking.
- the current approach demonstrated in the above examples requires a different nucleotide sequence to identify a backbone modification.
- Thioaptamer libraries were also created that only differ in the position of phosphate or dithioate but not in its base sequence. It has been shown that the positions of thiophosphates in a mixed backbone S-ODN can be determined by reaction of the S-ODN with iodoethanol followed by base catalyzed cleavage of the thiophosphate triester. This approach was used to identifying the location of monothio- and dithiophosphate linkages, independent of base sequence.
- thioaptamer bead-based hts of the host and pathogen proteome may be used with the thioselection technology (both enzymatic [S]-ODN and synthetic [S]-ODN /[S 2 ]-ODN) to develop thioaptamers targeting very important proteins (e.g., NF- ⁇ B and AP-1) to identify promising therapeutic leads.
- thioaptamer bead-based HTS of the proteomes with specialized high-throughput multicolor flow cytometry/bead sorting in conjunction with SELDITM mass-spectrometric methods to identify potential new therapeutic targets both of proteins involved in the immune response to BT viruses as well as viral proteins.
- Thioaptamers may be identified to inhibit the differentially expressed proteins in host-pathogen interactions as well as underlying immune response processes and so ameliorate cytopathological immune responses resulting in shock or to enhance "innate immunity" to help mount a more effective immune response.
- Mass spectrometric protein detection technology can be used to identify bound proteins using HTS of thioaptamer beads. This approach has significant advantages, since MS is more sensitive than fluorescent imaging and will be very useful for low-abundance proteins. In addition, if more than one protein binds to a given thioaptamer bead, then it will be possible to identify and quantify these proteins by SELDI. This is particularly helpful for identifying non-covalent dimers such as NF- ⁇ B or AP-1 (there are 22 different monomeric forms of AP-1 and thus in principle 100's of different combinations of dimers possible).
- non-covalent dimers such as NF- ⁇ B or AP-1 (there are 22 different monomeric forms of AP-1 and thus in principle 100's of different combinations of dimers possible).
- Thioaptamer proteomic arrays were used to demonstrate the use of ProteinChip array technology (e.g., Ciphergen) for protein identification of modified thioaptamer beads or surfaces.
- SELDI MS combines the well-established principles of solid-phase extraction and time-of-flight mass spectrometry in a process known as surface enhanced laser desorption/ionization time-of-flight mass spectrometry.
- ProteinChip Arrays may be customized by covalently attaching affinity reagents such as the modified thioaptamers to the spot surface. If the biological marker to be detected is known and thioaptamer affinity reagents are available, affinity surfaces can be designed to make use of this specific thioaptamer-protein interaction. Also, because SELDI uses mass spectrometric detection, several assays can be multiplexed easily by taking advantage of the unique masses of each bound protein.
- High-throughput screening (HTS) of thioaptamer libraries by flow cytometry and SELDI Bead-based methods were used to identify both thioaptamer sequences and binding proteins in parallel, without the need to select one thioaptamer for each purified protein.
- a number of [S]-ODN or [S 2 ]-ODN combinatorial libraries are synthesized, each containing 10 6 to 10 9 different, but related members (or a library of library with up to 10 14 sequences).
- the solid-phase split synthesis described herein may be used to create thioaptamer-bound bead libraries (one bead, one sequence or one library) as above.
- Each library can be sufficiently different to provide high affinity and selectivity to a small number of cellular proteins (such as AP-1 or NF- ⁇ B-type sequences).
- One or more of the thioaptamer library beads are incubated with cellular extracts, washed thoroughly to remove weakly bound proteins and the bound proteins visualized by direct fluorescent staining with cy3, cy5, SYPRO Ruby, or other newer dyes for high sensitivity (sub-nanogram). Fluorescently stained beads can be sorted in the high-speed cell/bead sorter for the top 10 2 or more beads which have the highest amount of bound protein.
- the thioaptamer sequence on the bead can be determined by the PCR "one bead sequencing" method disclosed herein.
- a random library of "sticky beads” is selected and an extract containing the complete proteome to identify both the thioaptamer sequence on the single beads and the protein(s) bound.
- HTS of combinatorial libraries to protein mixtures Besides using cell extracts, known mixtures of hundreds of commercially available proteins (cytokines, transcription factors, etc.) may be applied to the mixture of thioaptamer bead libraries. HTS cell/bead sorting is used followed by MS identification of bound proteins. This involves direct SELDI determination of the protein or peptide fragmentation methods followed by MS identification of bound proteins.
- thioaptamers rather than beads with proteins or monoclonal antibodies attached to them is that proteolysis and MS peptide identification is not complicated by proteolysis of bait proteins or Mab's.
- the thioaptamer-based multi-color flow cytometry HTS may also be used for targeting differentially expressed proteins within the host and pathogen proteomes, combined with MS detection (SELDI).
- the thioaptamer bead-based combinatorial library can be used in conjunction with fluorescent tagging of proteins followed by SELDI MS to identify proteins differentially expressed in control vs. virus infected cells.
- a combinatorial library (or a combinatorial library of libraries) of thioaptamer beads may be synthesized, each bead with a single thioaptamer sequence (or a combinatorial library of thioaptamer sequences on each bead).
- Up to 10 8 beads can be created with a single thioaptamer sequence on each bead.
- Cell extracts of a sample such as uninfected cells is labeled fluorescently with a dye (cy3 for example) as carried out previously and a virus-infected cell extract is then labeled fluorescently with another dye (cy5 for example). Both cell extracts are mixed together and allowed to bind to the bead thioaptamer library.
- two-color flow cytometry is used to compare cy3/cy5 color levels of each bead. If cy3/cy5 level differs significantly (> 2-fold) from 1, then the bead was captured.
- SELDI MS will be used to characterize the bound target further.
- SELDI MS can be used to determine which proteins have been bound to selected combinatory thioaptamer libraries and also used with single bead PCR to identify which bead(s) in the combinatorial library have bound to protein(s).
- Ciphergen's ProteinChip epoxy modified surfaces may be used to covalently attach 5'-amino-linker thioaptamers to beads.
- HTS of thioaptamers targeting differentially expressed proteins in the proteome in virus infected cells relative to treated cells (“High Throughput Pharmacoproteomics").
- three-color thioaptamer library bead sorting is used.
- a combinatorial library (or a combinatorial library of libraries) of thioaptamer beads is synthesized, each bead with a single thioaptamer sequence (or a combinatorial library of thioaptamer sequences on each bead). Up to 10 8 beads with a single thioaptamer sequence on each bead (or 10 14 sequences on the library of libraries) are made.
- Uninfected cell extracts are labeled fluorescently with a cy3 for example.
- a virus- infected cell extract (or any disease cell extract such as cancerous cells) is labeled fluorescently with cy5, and then a thioaptamer therapeutic treated, virus infected (or other disease) cell culture is labeled with a third dye.
- the three proteome cell extracts are mixed together in equal total protein quantities and allowed to bind to the bead thioaptamer library (or library of libraries). Three-color flow cytometry is used to compare cy3/cy5/dye 3 color levels of each bead. If cy3/cy5 level differs from 1 (uninfected vs.
- a complex of combinatorial libraries are created in which multiple transcription factor-like sequences with varying thiophosphate substitution patterns are concatenated in a single long sequence so that it can bind to multiple transcription factors such as NF- ⁇ B, AP-1, SP-1, GRE, SRE, etc., requiring a thioaptamer sequence of at least 20-40-mers.
- These embodiments provide an attractive approach to defining therapeutic strategies in which multiple proteins can be targeted with multiple thioaptamers.
- Such a combination (adjuvant) of drug therapeutics is needed to improve immune responses in cancer, AIDS, etc.
- Mammalian protein signaling pathways are often redundant so that if one pathway is affected, another can take over control. By perturbing multiple, highly interwoven pathways, a greater opportunity to modulate the immune response network is made available.
- HTS High-throughput screening
- thioaptamer beads using high-speed multicolor flow cytometry/cell sorting is used.
- more than 10 10 beads could be screened within a single day, and specific bead subpopulations could be sorted for subsequent proteomics analysis.
- This group also has considerable experience in HTS of cells and bacteria (as well as beads) for subsequent molecular characterizations by PCR and gene expression microarray analysis.
- Advanced HTS technologies may be used for large library screening and functional genomics.
- Single-cell (or bead) sorting of rare subpopulations may be used to isolate single beads from combinatorial libraries.
- a special high speed sorter uses a unique two-stage signal processing system, configured in hardware as a single layer neural network, which allows for sophisticated cell or bead classifications based on multivariate statistics or learning through neural networks.
- a 6-color high-speed flow cytometer/cell sorter is configured in hardware and software as a single-layer neural network that can also be used to generate real-time sort decisions on the basis of multivariate statistical classification functions. While it can perform the usual two-way sorts it is commonly used in "straight-ahead" sorting mode to allow for extremely high sort recovery and purity at high throughput rates or to efficiently sort single cells for cloning or for subsequent molecular characterizations by PCR.
- sorted "positive" beads can be subjected to SELDI-MS analysis to confirm the identity of the proteins bound to the thioaptamer beads of the present invention (via MALDI MS molecular ion characterization).
- SELDI-MS may be used to identify this event through the detection of multiple molecular ions.
- LC/MS/MS Liquid Chromatography/Tandem Mass Spectrometry
- Peptides are subsequently eluted from the RF column directly into the MS, either for mass fingerprinting, or for MS/MS sequence analysis.
- This LC tandem MS procedure is very useful for small amounts (femtomol) of complex.
- Yet another procedure is tandem LC/tandem MS.
- the proteomes can be either human, GP, hampster or mouse - human and mouse genome databases are available.
- 2D gel electrophoresis 2D PAGE can be conducted essentially as first described by (O'Farrell, 1975). High-throughput may be employed Pharmacia's IPGphor multiple sample IEF device or the first dimension, and Biorad's multiple gel SDS-PAGE systems (Protean Plus and Criterion dodeca cells) for the second. Gels will be stained with either SYPRO Ruby for high sensitivity (sub-nanogram) or Coomassie Blue when less sensitivity is required. Image analysis of gels will be achieved with a Perkin Elmer (PE) ProEXPRESS Proteomic Imaging System using Nonlinear's Progenesis imaging software.
- PE Perkin Elmer
- a Genomic Solutions' robotics recently purchased is utilized for protein spot picking and for sample trypsin hydrolysis (Proteomic Protein Picker), and sample clean-up, and sample application to MALDI plates (ProPrep 4 Block System).
- Mass fingerprinting for protein identification may use an Applied Biosystems (AB) matrix-assisted laser desorption/ionization (MALDI) time-of-flight (TOF) Voyager DE STR MS. Proteins will be identified with the Voyager's Prospector software. De novo sequencing and analysis of posttranslational modifications can be achieved by electrospray (ESI) MS/MS (capillary LC nanoflow option).
- MALDI matrix-assisted laser desorption/ionization
- TOF time-of-flight
- Isotope-coded affinity tags Some differential protein expression use isotope-coded affinity tags (ICATs) for quantitative analysis of complex protein mixtures (Gygi et al., 1999). In this procedure, there is an option to fractionate proteins before to proteolysis decreases the complexity of proteins analyzed.
- TNF Tumor Necrosis Factor
- Dyer R. B. and Herzog, N. K. (1995). Isolation of Intact Nuclei for Nuclear Extract Preparation from Fragile B-Lymphocyte Cell Lines. Biotechniques 19, 192-195.
- CRE Cyclic AMP Response Element-
- AP-1 AP-1 directed Transcription by CRE-transcription Factor Decoy Oligonucleotide
- RNA. 1, 317-326 Tian, Y., Adya, N., Wagner, S., Giam, C.Z., Green, M.R., & Ellington, A.D. (1995) "Dissecting proteimprotein interactions between transcription factors with an RNA aptamer," RNA. 1, 317-326.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47288803P | 2003-05-23 | 2003-05-23 | |
PCT/US2004/016246 WO2005018537A2 (fr) | 2003-05-23 | 2004-05-20 | Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1667729A2 true EP1667729A2 (fr) | 2006-06-14 |
EP1667729A4 EP1667729A4 (fr) | 2007-10-17 |
Family
ID=34215796
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04776088A Withdrawn EP1667729A4 (fr) | 2003-05-23 | 2004-05-20 | Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1667729A4 (fr) |
CA (1) | CA2526853A1 (fr) |
WO (1) | WO2005018537A2 (fr) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1635765B1 (fr) * | 2003-05-23 | 2013-07-17 | Board Of Regents, The University Of Texas System | Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere |
US8497250B2 (en) * | 2005-05-04 | 2013-07-30 | Noxxon Pharma Ag | Use of spiegelmers to inhibit an intracellular target molecule |
JP2012526130A (ja) * | 2009-05-05 | 2012-10-25 | アルテルムネ テクフノロジエス,エルエルシー | 化学的にプログラム可能な免疫 |
JP6591392B2 (ja) * | 2013-03-14 | 2019-10-16 | ソマロジック, インコーポレイテッドSomaLogic, Inc. | Il−6に結合するアプタマー及びil−6介在性状態の治療または診断におけるそれらの使用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026260A2 (fr) * | 2002-09-17 | 2004-04-01 | Archemix Corp. | Aptameres vih prophylactiques et therapeutiques |
WO2005003291A2 (fr) * | 2002-10-16 | 2005-01-13 | Board Of Regents Of The University Of Texas System | Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes |
WO2005032455A2 (fr) * | 2003-05-23 | 2005-04-14 | Board Of Regents | Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere |
WO2005037053A2 (fr) * | 2003-05-23 | 2005-04-28 | Board Of Regents - The University Of Texas System | Recherche systematique a haut debit, dans des echantillotheques d'aptameres, de liaisons specifiques avec des proteines sur des virus et d'autres pathogenes |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995026204A1 (fr) * | 1994-03-25 | 1995-10-05 | Isis Pharmaceuticals, Inc. | Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate |
EP0855184A1 (fr) * | 1997-01-23 | 1998-07-29 | Grayson B. Dr. Lipford | Composition pharmaceutique comprenant un polynucléotide et un antigène notamment pour la vaccination |
US20010034330A1 (en) * | 1998-08-10 | 2001-10-25 | Charlotte Kensil | Innate immunity-stimulating compositions of CpG and saponin and methods thereof |
US6514948B1 (en) * | 1999-07-02 | 2003-02-04 | The Regents Of The University Of California | Method for enhancing an immune response |
US6725526B2 (en) * | 2002-01-14 | 2004-04-27 | Hitachi Global Storage Technologies Netherlands B.V. | Method of forming microsuspension assemblies for direct access storage devices |
-
2004
- 2004-05-20 CA CA002526853A patent/CA2526853A1/fr not_active Abandoned
- 2004-05-20 EP EP04776088A patent/EP1667729A4/fr not_active Withdrawn
- 2004-05-20 WO PCT/US2004/016246 patent/WO2005018537A2/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004026260A2 (fr) * | 2002-09-17 | 2004-04-01 | Archemix Corp. | Aptameres vih prophylactiques et therapeutiques |
WO2005003291A2 (fr) * | 2002-10-16 | 2005-01-13 | Board Of Regents Of The University Of Texas System | Banques combinatoires d'aptameres a groupes phosphorothioate et phosphorodithioate oligonucleotidiques lies a des billes |
WO2005032455A2 (fr) * | 2003-05-23 | 2005-04-14 | Board Of Regents | Oligonucleoside phosphorothioate selectionnes de maniere combinatoire et a base structurelle et facteurs de transcription ap-1 ciblant un phosphorodithioate aptamere |
WO2005037053A2 (fr) * | 2003-05-23 | 2005-04-28 | Board Of Regents - The University Of Texas System | Recherche systematique a haut debit, dans des echantillotheques d'aptameres, de liaisons specifiques avec des proteines sur des virus et d'autres pathogenes |
Non-Patent Citations (2)
Title |
---|
KING DAVID J ET AL: "COMBINATORIAL SELECTION AND BINDING OF PHOSPHOROTHIOATE APTAMERS TARGETING HUMAN NF-KAPPA B RELA(P65) AND P50" BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 41, no. 30, 30 July 2002 (2002-07-30), pages 9696-9706, XP009084286 ISSN: 0006-2960 * |
See also references of WO2005018537A2 * |
Also Published As
Publication number | Publication date |
---|---|
WO2005018537A3 (fr) | 2005-05-26 |
CA2526853A1 (fr) | 2005-03-03 |
EP1667729A4 (fr) | 2007-10-17 |
WO2005018537A2 (fr) | 2005-03-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9567579B2 (en) | Structure based and combinatorially selected oligonucleoside phosphorothioate and phosphorodithioate aptamer targeting AP-1 transcription factors | |
US20060121489A1 (en) | High throughput screening of aptamer libraries for specific binding to proteins on viruses and other pathogens | |
Xiao et al. | Oligonucleotide aptamers: Recent advances in their screening, molecular conformation and therapeutic applications | |
JP4176466B2 (ja) | 前立腺特異的膜抗原に対する核酸リガンド | |
US8440801B2 (en) | Aptamer against IL-17 and use thereof | |
Hornung et al. | RNA recognition via TLR7 and TLR8 | |
Tavitian | In vivo imaging with oligonucleotides for diagnosis and drug development | |
JP2013507905A5 (fr) | ||
JP2010536335A (ja) | 活性が改善した組合せモチーフ免疫賦活性オリゴヌクレオチド | |
JP2008523094A (ja) | 哺乳類における免疫応答誘導組成物および方法、ならびに短鎖干渉rnaなどのオリゴヌクレオチド剤に対する免疫応答の回避方法 | |
EA008940B1 (ru) | Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей | |
US9303262B2 (en) | Methods for identifying aptamer regulators | |
US20080214489A1 (en) | Aptamer-mediated intracellular delivery of oligonucleotides | |
JP2022552192A (ja) | レチノイン酸誘導遺伝子iタンパク質に結合する核酸化合物 | |
EP1667729A2 (fr) | Aptamere a oligonucleoside phosphorothioate et phosphorodithioate selectionne de maniere combinatoire et selon la structure pour le ciblage des facteurs de transcription ap-1 | |
JP2023099157A (ja) | Adamts5に対するアプタマー及びその使用 | |
JP2023058675A (ja) | ウイルス感染及び活性抑制方法 | |
RU2501862C1 (ru) | Способ получения терапевтического агента для лечения клещевого энцефалита | |
KR101993427B1 (ko) | 백혈구에 선택적으로 결합하는 압타머 및 이의 용도 | |
CA2907636C (fr) | Aptamere pour il-17 et utilisation de celui-ci | |
WO2020204151A1 (fr) | Aptamère dirigé contre fgf9 et son utilisation | |
JPWO2020123816A5 (fr) | ||
US20050118611A1 (en) | Thioaptamers enable discovery of physiological pathways and new therapeutic strategies | |
Tavitian | In vivo imaging with oligonucleotides for diagnosis | |
Shu et al. | Fabrication methods for RNA nanoparticle assembly based on bacteriophage phi29 packaging RNA structural features |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20051220 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C12N 15/11 20060101AFI20070626BHEP |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20070917 |
|
17Q | First examination report despatched |
Effective date: 20090130 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20090610 |